Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Torcetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Torcetrapib SCHEMBL10041443 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL49081 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL126708 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL6277910 | 1.00 | CETP (1.00) | CETP | |
| Torcetrapib SCHEMBL7169875 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL18027496 | 0.97 | CETP (0.94) | CETP | |
| SCHEMBL12756768 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3185801 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187101 | 0.96 | CETP (0.92) | CETP | |
| Torcetrapib SCHEMBL3187095 | 0.96 | CETP (0.92) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3823631-B1 | METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | ASTRAZENECA AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4720063-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4656240-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Novartis AG (CH) | 2025-12-03 | — | — | EP | disclosed |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | ASTRAZENECA AB (SE) | 2025-11-18 | — | — | US | disclosed |
| EP-4436662-B1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY | 2025-08-07 | — | — | US | disclosed |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | HOFFMANN-LA ROCHE INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250136656-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250000794-A1 | IMPROVED DRUG PROCESSING METHODS TO INCREASE DRUG LOADING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-01-02 | — | — | US | disclosed |
| WO-2024241229-A1 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2024-11-28 | — | — | WO | disclosed |
| EP-4058448-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4058446-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| EP-4047023-A1 | IMPROVED PEPTIDE PHARMACEUTICALS | Eumederis Pharmaceuticals, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11401554-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | HOFFMAN-LA ROCHE INC. (US) | 2022-08-02 | — | — | US | disclosed |
| CN-110229104-B | Method for synthesizing tetrahydroquinoline compound by catalyzing arylamine and alpha-keto ester with cyclopentadienyl titanium/Bronsted acid | 陕西师范大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-109843887-B | Nalidinone derivatives and their use in the treatment of cardiac arrhythmias | 诺华股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114381512-A | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents | 豪夫迈·罗氏有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | PLD1, PLD2, NAPEPLD | CETP 1130/4885 |
| US-12472194-B2 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | SLC5A2, SLC5A1, FABP3 | CETP 660/4885 |
| US-12371748-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CETP 3469/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CETP 3725/4885 |
| US-11401554-B2 | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | CETP, HDLBP, APOB | CETP 1/4885 |
| US-20250136656-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | CETP 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.